Abstract
Radiation therapy improves survival in high-grade gliomas but most patients relapse and usually within radiation fields. This may be due to uncertainties in target delineation and difficulties in identifying radioresistant regions for dose escalation. The use of T1 and T2-weighted magnetic resonance imaging (MRI) coregistration on the planning CT improves the target volume definition but magnetic resonance spectroscopic imaging (MRSI) and other types of metabolic and functional imaging (perfusion MRI, diffusion-weighted MRI, positron emission tomography (PET) imaging) may give useful additional information for target delineation. This article focuses on the potential of each imaging modality: assessment of response to treatment, detection of abnormalities not seen on MRI, predictive value for the site of local relapse. The incorporation of such techniques may improve target volume definition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
